What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Mari Mino-Kenudson mainly focuses on Cancer research, Pathology, Internal medicine, Adenocarcinoma and Anaplastic lymphoma kinase.
Mari Mino-Kenudson interconnects Molecular biology, KRAS, Colorectal cancer, Gefitinib and Drug resistance in the investigation of issues within Cancer research.
The Pathology study combines topics in areas such as Intraductal papillary mucinous neoplasm, Pancreatic disease and Pancreas.
Her Internal medicine research incorporates themes from Gastroenterology and Oncology.
Her Adenocarcinoma study incorporates themes from Fluorescence in situ hybridization and Pancreatectomy.
In her study, ROS1 and Gene rearrangement is inextricably linked to Crizotinib, which falls within the broad field of Anaplastic lymphoma kinase.
Her most cited work include:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer (3607 citations)
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2242 citations)
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK (1441 citations)
What are the main themes of her work throughout her whole career to date?
Mari Mino-Kenudson focuses on Pathology, Internal medicine, Cancer research, Radiology and Oncology.
Her Pathology study combines topics from a wide range of disciplines, such as Intraductal papillary mucinous neoplasm, Pancreas and Adenocarcinoma.
Her work on Gastroenterology expands to the thematically related Internal medicine.
Her Cancer research study which covers Anaplastic lymphoma kinase that intersects with Crizotinib.
Her research is interdisciplinary, bridging the disciplines of Clinical trial and Oncology.
The study incorporates disciplines such as Lung and Epidermal growth factor receptor in addition to Lung cancer.
She most often published in these fields:
- Pathology (34.13%)
- Internal medicine (26.94%)
- Cancer research (21.03%)
What were the highlights of her more recent work (between 2019-2021)?
- Internal medicine (26.94%)
- Oncology (17.16%)
- Pathology (34.13%)
In recent papers she was focusing on the following fields of study:
Mari Mino-Kenudson spends much of her time researching Internal medicine, Oncology, Pathology, Lung cancer and Cancer research.
Her Internal medicine study frequently links to other fields, such as Gastroenterology.
Her research integrates issues of Neoadjuvant therapy, Immune checkpoint inhibitors, FOLFIRINOX and Perineural invasion in her study of Oncology.
Mari Mino-Kenudson studied Pathology and Adenocarcinoma that intersect with Prognostic factor and Carcinoma.
In Lung cancer, Mari Mino-Kenudson works on issues like Lung, which are connected to Stage.
The concepts of her Cancer research study are interwoven with issues in Cancer, Cell, In vitro, Transcriptome and Pancreatic ductal adenocarcinoma.
Between 2019 and 2021, her most popular works were:
- PD-L1 Testing for Lung Cancer in 2019 : Perspective From the IASLC Pathology Committee (57 citations)
- SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. (42 citations)
- PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer (42 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Lung cancer, Oncology, Cancer research and Pathology.
Her study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
Mari Mino-Kenudson has researched Lung cancer in several fields, including Programmed cell death 1, KRAS, Lung, Cohort and Immunotherapy.
Her Oncology study combines topics in areas such as FOLFIRINOX, Mutation, Pancreatic ductal adenocarcinoma, Perineural invasion and Lymphovascular.
Her Cancer research research incorporates elements of Cell, Reprogramming, Vitamin D3 Receptor, Low-dose chemotherapy and Performance status.
Her Pathology research includes elements of Ovarian tumor and ARID1A.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
